» Articles » PMID: 2034246

Mutations in the Precore Region of Hepatitis B Virus DNA in Patients with Fulminant and Severe Hepatitis

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1991 Jun 13
PMID 2034246
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The presence of the hepatitis B e antigen (HBeAg) in serum is known to be a marker of a high degree of viral infectivity. However, fulminant hepatitis may occur in persons who are negative for HBeAg. A single point mutation has been reported to produce a stop codon in the precore region of hepatitis B virus DNA and prevent the formation of the precore protein required to make HBeAg. To determine whether a precore-mutant virus is causally related to severe liver injury, we analyzed the entire precore region in viral strains isolated from patients with fatal cases and uncomplicated cases of hepatitis B.

Methods: Serum was obtained from 9 patients with fatal hepatitis B (5 with fulminant and 4 with severe exacerbations of chronic hepatitis) and 10 patients with acute, self-limited hepatitis B. Serum samples from a sex partner implicated as the source of the virus in one case of fulminant hepatitis were also studied. The 87 nucleotides in the precore region of the hepatitis B virus were amplified by the polymerase chain reaction and then directly sequenced.

Results: Of the nine patients with fatal hepatitis, seven had retrievable hepatitis B DNA: In all seven there was a point mutation from G to A at nucleotide 1896 of the precore region, converting tryptophan (TGG) to a stop codon (TAG). In contrast, this mutation was not found in the 10 patients with acute, self-limited hepatitis B. The hepatitis B DNA from the implicated source contained a sequence with the stop-codon mutation that was identical to the sequence in her partner, who had fulminant hepatitis.

Conclusions: The presence of a mutant viral strain is associated with and may be involved in the pathogenesis of fulminant hepatitis B and severe exacerbations of chronic hepatitis B.

Citing Articles

Potential Biomarkers and Therapeutic Targets in Hepatitis B Virus-related Acute Liver Failure: Interplay of the Ferroptosis, Autophagy and Immune Responses.

Zuo J, Tian Y, An Q, Wu B, Yang J, Fan Y Int J Med Sci. 2025; 22(4):806-818.

PMID: 39991755 PMC: 11843133. DOI: 10.7150/ijms.106360.


HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.

Uchida T, Imamura M, Hayes C, Suehiro Y, Teraoka Y, Ohya K Hepatology. 2023; 78(3):929-942.

PMID: 36896966 PMC: 11519831. DOI: 10.1097/HEP.0000000000000335.


The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection.

Amano H, Kanda T, Mochizuki H, Kojima Y, Suzuki Y, Hosoda K Viruses. 2021; 13(11).

PMID: 34835022 PMC: 8624674. DOI: 10.3390/v13112216.


Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection.

Kosinska A, Festag J, Muck-Hausl M, Festag M, Asen T, Protzer U Vaccines (Basel). 2021; 9(8).

PMID: 34451966 PMC: 8402308. DOI: 10.3390/vaccines9080841.


The dynamic change of antibody index against Covid-19 is a powerful diagnostic tool for the early phase of the infection and salvage PCR assay errors.

Omata M, Hirotsu Y, Sugiura H, Maejima M, Nagakubo Y, Amemiya K J Microbiol Immunol Infect. 2021; 54(5):830-838.

PMID: 33593710 PMC: 7784537. DOI: 10.1016/j.jmii.2020.12.009.